Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Medical Device

Power3 Medical in licensing negotiations for blood tests

This article was originally published in Clinica

  • News
  • Joseph Harvey  

Executive Summary

Power3 Medical Products, the developer of tests for cancer and neurodegenerative diseases, is currently in talks with unnamed "leading" distributors for the marketing of its disease detection blood tests. Houston, Texas-based Power3 indicated that it was confident the negotiations will result in deals being inked. The firm said that there had been particular interest in its early diagnostic test for breast cancer. Power3 also manufactures blood tests for Alzheimer’s and Parkinson’s disease.

Table

View full table

Topics

Tags:
Medical Device
Latest Headlines

Global Medtech Guidance Tracker: April 2024

Front Line Medical Technologies Announce CE Mark For COBRA-OS

Recalls Round-Up: Class 1s For BioMérieux, Fresenius, Draeger, More

New Guidance For Breast Cancer Screening Drops Age Of First Scan To 40

See All
UsernamePublicRestriction

Register

MT041560

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By